11-08-2018 08:43 PM CET - Health & Medicine
Print

Human Chorionic Gonadotropin (hCG) Market Growth and Revenue Analysis By Top Key Players Bristol Myers Squibb Company, Merck & Co., Ferring B.V., Fresenius Kabi AG, Cigna, Sun Pharmaceutical, Lee BioSolutions Inc. & Others

Press release from: Allied Market Research

Rise in the incidence of male hypogonadism among the geriatric population is the key factor driving the market growth. In addition, increase in traction gained by hCG among healthcare professionals and patients would supplement the market growth. However, cautions and warnings issued by the FDA pertaining to the side effects of hCG therapy is expected to hamper the market growth. Moreover, untapped economies are set to offer lucrative opportunities for the expansion of the hCG market.

Download PDF Report Sample @ www.alliedmarketresearch.com/request-sample/3418

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. Human chorionic gonadotropin (hCG) belongs to the family of gonadotropin hormones and is naturally produced by the placenta. hCG hormone plays a pivotal role after the formation of the embryo, and hence has gained significant traction over the years for the treatment of infertility in women and men. hCG triggers ovulation in women and assists in increasing the sperm count in men.

Based on technology, the market is divided into natural source extraction and recombinant technology. The recombinant technology segment is expected to register the highest growth rate during the forecast period. However, the natural source extraction segment dominated the global market in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to easy and low-cost availability of hCG from pregnant womens urine and placenta cells.

Based on the therapeutic area, the global market is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Male hypogonadism segment is anticipated to witness highest growth rate in the global market, owing to high susceptibility of geriatric population to hypogonadism. However, female infertility treatment dominated the therapeutic area segment in 2017, owing to surge in female infertility-related problems such as polycystic ovaries, hormonal imbalance, and others.

Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, surge in disposable income, and rise in awareness toward infertility treatment procedures. In addition, rise in fertility tourism in Asia-Pacific countries such as Thailand and Malaysia boosts the market growth.

Get Customized Report @ www.alliedmarketresearch.com/request-for-customization/3418

The major companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., Ferring B.V., Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Lee BioSolutions Inc., Sanzyme, Scripps Laboratories, and Lupin AB. The other players operating in the global human chorionic gonadotropin (hCG) market include Kamiya Biomedical Company, Intas Pharmaceuticals, Prospec-Tany Technogene Ltd., Cipla Limited, Biocare Medical, LLC, MyBioSource, Zydus Cadila, and Life Medicare & Biotech Pvt. Ltd.

LIST OF TABLES

TABLE 01. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 02. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR NATURAL SOURCE EXTRACTION, BY REGION, 2017-2025 ($MILLION)
TABLE 03. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RECOMBINANT TECHNOLOGY, BY REGION, 2017-2025 ($MILLION)
TABLE 04. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 05. HUMAN CHORIONIC GONADOTROPIN MARKET FOR FEMALE INFERTILITY TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 06. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OLIGOSPERMIC TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 07. HUMAN CHORIONIC GONADOTROPIN MARKET FOR MALE HYPOGONADISM, BY REGION, 2017-2025 ($MILLION)
TABLE 08. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)
TABLE 09. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 10. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR FERTILITY CLINICS, BY REGION, 2017-2025 ($MILLION)
TABLE 11. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RESEARCH INSTITUTES, BY REGION, 2017-2025 ($MILLION)
TABLE 12. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)
TABLE 13. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 14. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 15. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 16. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 17. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 18. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 19. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 20. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 21. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 22. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 23. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 24. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 25. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 26. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 27. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 28. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 29. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 30. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 31. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 32. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 33. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 34. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 35. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 36. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 37. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 38. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 39. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 40. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 41. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 42. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 43. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 44. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 45. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 46. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 47. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 48. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 49. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 50. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 51. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 52. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 53. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 54. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 55. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 59. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 60. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 61. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 62. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 63. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 64. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 65. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 66. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 67. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 68. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 69. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 70. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 71. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 72. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 73. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 74. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 75. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 76. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 77. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 78. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 79. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 80. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 81. BRISTOL MYERS: COMPANY SNAPSHOT
TABLE 82. FERRING: COMPANY SNAPSHOT
TABLE 83. FERRING: OPERATING SEGMENTS
TABLE 84. FERRING: PRODUCT PORTFOLIO
TABLE 85. MERCK: COMPANY SNAPSHOT
TABLE 86. MERCK: OPERATING SEGMENTS
TABLE 87. MERCK: PRODUCT PORTFOLIO
TABLE 88. FRESENIUS: COMPANY SNAPSHOT
TABLE 89. FRESENIUS: PRODUCT PORTFOLIO
TABLE 90. CIGNA: COMPANY SNAPSHOT
TABLE 91. CIGNA: OPERATING SEGMENTS
TABLE 92. SUN PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 93. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 94. LEE: COMPANY SNAPSHOT
TABLE 95. LEE: PRODUCT SEGMENTS
TABLE 96. LEE: PRODUCT PORTFOLIO
TABLE 97. SANZYME: COMPANY SNAPSHOT
TABLE 98. SANZYME: PRODUCT SEGMENTS
TABLE 99. SANZYME: PRODUCT PORTFOLIO
TABLE 100. SCRIPPS: COMPANY SNAPSHOT
TABLE 101. SCRIPPS: PRODUCT SEGMENTS
TABLE 102. SCRIPPS: PRODUCT PORTFOLIO
TABLE 103. LUPIN: COMPANY SNAPSHOT
TABLE 104. LUPIN: PRODUCT PORTFOLIO

Access Full Summery @ www.alliedmarketresearch.com/press-release/human-chorioni...

About Us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.
News-ID: 1357586 • Views: 550
More releases More releases

You can edit or delete your press release here: